B+
Bull case
20%
Probability
Target price
$170.00
Analysis reference price unavailable
Analysis 2026-02-11 · RankAlpha Sentiment AI
GILD
Gilead SciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$146.84
Analysis reference price unavailable
Analysis 2026-02-11 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$103.00
Analysis reference price unavailable
Analysis 2026-02-11 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-02-11
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+62.7
Score
AI commentary
Market tone is mixed: consensus median sits near our base case while select broker upgrades have pushed upside expectations toward the high‑$160s–$170s, signaling selective conviction on HIV strength [#SERP-4][#SERP-6]. The wide low–high spread reflects event-driven risk; near-term earnings and readouts will likely determine short-term direction.
RankAlpha Sentiment AI - 2026-02-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-12eventNext quarterly results (estimated)Medium impact
Estimated quarterly results event; date conservatively assumed as 2026-05-12 (no confirmed date disclosed here). Results can re-price shares if HIV/oncology revenues diverge from expectations [#SERP-4].
2027-02-11catalystHIV franchise sustained growth (Biktarvy/Cabenuva)High impact
Continued HIV product momentum could drive significant top-line upside over the next 12 months; recent analyst notes cite strong HIV sales as a reason for higher targets [#SERP-6].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-11 • Updated nightlySource: Internal modelMethodology